Venue: Room Swan, Kyoto International Conference Center
Fee: Ticket JPY1,000 for each roundtable discussion.
Breakfast is provided.
9 seats (8 seats for RT-27-5) are available for each and it is first come first served.
No refund will be made.

Monday, September 25    7:30am - 8:30am

RT-25-1

Eberhard Wieland
Klinikum Stuttgart, Germany
Lymphocyte surface molecules as immune activation biomarkers in solid organ transplantation
(9-seat available)

RT-25-2

Hartmut Derendorf
University of Florida, USA
How to write a good article
(9-seat available)

RT-25-3

Roger Jelliffe
University of Southern California, USA
Individualized drug therapy
(9-seat available)

RT-25-4

Michael N. Neely
Children's Hospital Los Angeles, USA
Optimal sampling and dosing for individual patients
(9-seat available)

RT-25-5

Philip Patsalos
University College London, UK
Antiepileptic drug TDM: Current practice and future prospectives
(9-seat available)

RT-25-6

Shinya Ito
The Hospital for Sick Children, Canada
Drug monitoring in pregnancy and lactation
(9-seat available)

RT-25-7

Vanessa Steenkamp
University of Pretoria, South Africa
Assay and screening for drug abuse
(9-seat available)

RT-25-8

William Clarke
Johns Hopkins University School of Medicine, USA
Development and validation of clinical LC-MS assays – Consensus guidelines from CLSI
(9-seat available)

Tuesday, September 26    7:30am - 8:30am

RT-26-1Cancelled

Alexander Vinks
Cincinnati Children’s Hospital Medical Center, USA
Precision medicine in pediatrics
(9-seat available)

RT-26-2

Etienne Chatelut
Institut Universitaire du Cancer de Toulouse, France
Clinical pharmacology of anticancer agents: benefits and limits of TDM

RT-26-3

Hans Maurer
Saarland University, Germany
Clinical or forensic toxicology – What''s the difference?
(9-seat available)

RT-26-4

Ikumi Tamai
Kanazawa University, Japan
Systemic effect of hepatic transporter and enzyme interplay
(9-seat available)

RT-26-5

Kamisha Johnson-Davis
University of Utah, c/o ARUP Laboratories, USA
Cannabis
(9-seat available)

RT-26-6

Mercè Brunet
Hospital Clínic of Barcelona, Spain
What we must improve to be able to implement biomarkers that facilitate a personalized immunosuppression?
(9-seat available)

RT-26-7

Uwe Christians
University of Colorado, USA
Therapeutic drug monitoring - A journal of personalized drug therapy
(9-seat available)

Wednesday, September 27    7:30am - 8:30am

RT-27-1

Charles Arthur Peloquin
University of Florida, USA
TDM of anti-tuberculosis treatment
(9-seat available)

RT-27-2

Hirotoshi Echizen
Meiji Pharmaceutical University, Japan
Individualization of warfarin dosing
(9-seat available)

RT-27-3

Manuela Neuman
University of Toronto, Canada
Mitochondrial toxicity-liver toxicity
(9-seat available)

RT-27-4

Tomasz Pawinski
Medical University of Warsaw, Poland
Implication of pharmacokinetics of immunosuppressive agents on TDM
(9-seat available)

RT-27-5

Tsuyoshi Fukuda and Chie Emoto
Cincinnati Children's Hospital Medical Center, USA
Improving pediatric dosing through allometric scaling, PopPK and PBPK modeling
(8-seat available)

RT-27-6

Tsuyoshi Shiga
Tokyo Women's Medical University, Japan
Clinical uses of amiodarone
(9-seat available)

RT-27-7

Yasutsuna Sasaki
Showa University, Japan
Clinical trials for anticancer agents
(9-seat available)